Sopharma sells over half a million treasury shares

Vesela Lyubenova Stoeva Deputy Chairman of the Board of Directors Sopharma AD
Vesela Lyubenova Stoeva Deputy Chairman of the Board of Directors - Sopharma AD
0Comments

Sopharma AD has announced the sale of a significant portion of its treasury shares. On July 2, 2025, the company sold 518,619 repurchased shares. This transaction accounts for 0.29% of the company’s share capital and was executed on the Bulgarian Stock Exchange.

The total value of the shares sold amounted to BGN 3,640,994.86, with an average price per share of BGN 7.02.

Following this sale, Sopharma’s total number of treasury shares stands at 8,894,963, which represents 4.95% of the company’s share capital.

“Sopharma” AD is listed on both the Bulgarian Stock Exchange (SFA) and Warsaw Stock Exchange (SPH).



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.